First Approval of 2d-Line Remedy for DLBCL
The FDA granted accelerated acclaim for tafasitamab (Monjuvi), the first current 2d-line treatment for relapsed or refractory diffuse gigantic B-cell lymphoma (DLBCL). A CD19-centered cytolytic antibody, tafasitamab has acclaim to be used in combination with lenalidomide (Revlimid) in adults who…